TrialOrphanet journal of rare diseases2020

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.

Teresa Coelho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.